^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/30/2014
Excerpt:
Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Excerpt:
MEKINIST as a monotherapy is indicated for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma and in whom either there is intolerance to BRAF inhibitors or BRAF inhibitors cannot be used.
Source:
Title:
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
Excerpt:
...- Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do Excludes: Pancreatic cancer patients, colorectal cancer patients, or BRAF V600E melanoma patients who have failed BRAF inhibitors - Must have completed any prior treatments 28 days or more before study entry. ...
Trial ID:
Source:
Title:
A study of GSK1120212 compared with chemotherapy in patients with BRAF mutation positive advanced or metastatic melanoma
Excerpt:
...Histologically confirmed, Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory. ...
Trial ID:
